Telomir Pharmaceuticals, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported net loss was USD 6.25 million compared to USD 0.482938 million a year ago. Basic loss per share from continuing operations was USD 0.23 compared to USD 0.02 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.33 USD | +15.47% | -9.98% | 0.00% |
02/07 | Telomir Pharmaceuticals Joins Russell 3000, Microcap Indexes | MT |
01/07 | Telomir Pharmaceuticals, Inc.(NasdaqCM:TELO) added to Russell Small Cap Comp Value Index | CI |
1st Jan change | Capi. | |
---|---|---|
0.00% | 11Cr | |
+56.89% | 81TCr | |
+39.52% | 62TCr | |
-6.55% | 35TCr | |
+7.92% | 29TCr | |
+13.74% | 24TCr | |
+13.83% | 22TCr | |
-0.49% | 22TCr | |
+7.94% | 17TCr | |
-2.57% | 16TCr |
- Stock Market
- Equities
- TELO Stock
- News Telomir Pharmaceuticals, Inc.
- Telomir Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024